Dizal (jiangsu) Pharmaceutical Co. Ltd. Class ASSE: 688192

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Shareholding Reduction Plan of Directors and Senior Management

Sep 4, 2026 · Issued by Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Shareholding Reduction Plan of Directors and Senior Management

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A

"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance by the U.S. FDA of the Supplemental New Drug Application for Sunvozertinib as a Monotherapy for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsAug 31
Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026Aug 21
"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Meeting of the 3rd Board of DirectorsAug 21
"DIZAL PHARMACEUTICAL CO., LTD."Announcement on Providing Guarantee for Controlled SubsidiaryAug 5

All Dizal (jiangsu) Pharmaceutical Co. Ltd. Class A news releases